Barclays Maintains Overweight on ERock, Lowers Price Target to $22
Barclays analyst Christine Cho maintains ERock (NYSE:EROC) with a Overweight and lowers the price target from $23 to $22.
Follow the latest ERock, Inc. (EROC) news and market headlines alongside the live EROC price. Stay informed on what's moving EROC.
Barclays analyst Christine Cho maintains ERock (NYSE:EROC) with a Overweight and lowers the price target from $23 to $22.
Evercore ISI Group analyst Nicholas Amicucci maintains ERock (NYSE:EROC) with a Outperform and lowers the price target from $28 to $20.
ERock Inc (NYSE:EROC) shares are falling Thursday after the onsite power provider delivered a split third-quarter report. Here's what you should know.
ERock (NYSE:EROC) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
ERock (NYSE:EROC) affirms FY2026 sales outlook from $435.000 million-$465.000 million to $435.000 million-$465.000 million vs $451.559 million estimate.
ERock (NYSE:EROC) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.01) by 500 percent. The company reported quarterly sales of $152.767 million which missed the analyst
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to EROC, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.